Comparing the Effectiveness of Ferric Pyrophosphate and Ferrous Bis-Glycinate in Non-Dialysis Chronic Kidney Disease Patients

Asian Journal of Pharmaceutical and Health Sciences,2020,10,1,2220-2223.
Published:June 2020
Type:Research Article
Author(s) affiliations:

Aiswarya VV1*, Amitha VV1*,Devika Krishna S1*, N Premkumar,Iqbal Ahmad2

1College of Pharmaceutical sciences, Govt. Medical college Kannur, Kerala1.

2Dept. of Pharmacy practice, College of Pharmaceutical sciences, Kannur, Kerala and Dept. of Nephrology, Govt. Medical College Kannur, Kerala


Introduction: Iron deficiency anaemia is common and consequential in nondialysis-dependent CKD (NDD-CKD), and are associated with higher risks of progressive loss of kidney function, cardiovascular events, and mortality. Aim: Comparing the effectiveness of Ferric pyrophosphate and Ferrous bis-glycinate in non-dialysis chronic kidney disease patients and to observe the side effect profile of both the drugs. Methodology: A prospective study was conducted in the outpatient Dept. of Nephrology at Govt. Medical College, Kannur. The patients were grouped into two cohorts. Those patients prescribed with Ferric pyrophosphate (Ferisome) and Ferrous bis-glycinate (Bizfer XT) were included. Anemia profile–Ferritin, % Transferrin saturation and serum creatinine were collected and documented and the patients were observed for adverse reactions during monthly outpatient visits. Result: A total of 67% patient completed the study. Both the drugs had shown clinical improvement in the anemia profile and haemoblobin level. By comparing, Ferrous bisglycinate shows better improvement than Ferric pyrophosphate. ADRs were observed in patients on both the drugs. Conclusion: The study conclude that Ferrous bis-glycinate (Bizfer) is more effective than Ferric pyrophosphate (Ferisome) and is cost effective than latter.

Observed ADR of both study drugs